Drug Discovery Technologies Market Size, Growth, Share & Trends Analysis
Report Code
BT 9934
Published in
Jan, 2026, By MarketsandMarkets™
Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030
USD 51.51 BN
MARKET SIZE, 2030
CAGR 11%
(2025-2030)
450
REPORT PAGES
400
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Drug Discovery Technologies market, valued at US$28.61 billion in 2024, stood at US$30.58 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$51.51 billion by the end of the period The growth of the drug discovery technologies market is driven by the broader use of advanced screening platforms and rising demand for biologics, cell and gene therapies, and RNA-based drugs. The increased adoption of 3D cultures and organoids requires advanced image-based analysis, which boosts demand for high-content screening systems and drives higher adoption of instruments, software, and services across the market.
KEY TAKEAWAYS
-
By RegionNorth America accounted for the largest share of the drug discovery technologies market in 2024. The growth in this segment is driven by strong pharmaceutical R&D, advanced infrastructure, high biotech investments, supportive regulations, and the presence of key global players that drive the adoption of cutting-edge technologies.
-
By ProductBy product, the reagents & consumables segment accounted for the largest share of the drug discovery technologies market in 2024. This growth in this segment is driven by the repeated and routine use of reagents and consumables across screening, assay development, and validation activities in drug discovery.
-
By TechnologyBy technology, the high-throughput screening technologies segment accounted for the largest share of the drug discovery technologies market in 2024. This prominence is driven by its ability to rapidly test large compound libraries, reduce drug development time, improve efficiency, and support early-stage target identification, making it essential in modern drug discovery processes.
-
By Therapeutic AreaBy therapeutic area, the oncology segment accounted for the largest share of the drug discovery technologies market in 2024. The growth of this segment is driven by the high cancer prevalence, increasing investment in targeted therapies, growing demand for personalized medicine, and intensive research efforts.
-
Competitive LandscapeThermo Fisher Scientific Inc., Danaher Corporation, and Agilent Technologies, Inc. were identified as some of the star players in the drug discovery technologies market, given their strong market share and service footprint.
-
Competitive LandscapeGenScript, Schrodinger, Inc., and BICO, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The drug discovery technologies market is growing due to the adoption of advanced screening platforms, a rising focus on biologics, cell and gene therapies, and RNA drugs, as well as increased use of 3D cultures and organ-on-chip models, and ongoing improvements in assay miniaturization and laboratory automation.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The drug discovery market is shifting from conventional low-throughput screening tests to AI/ML-enabled target discovery. Adoption of 3D cell culture models, organoids, and high-content screening is increasing. Additionally, higher demand is projected for faster and more predictive research, with automated analysis of research results and cloud-enabled solutions. Furthermore, improved target identification, accelerated discovery, increased clinical success rate, and better reproducibility fueled growth in this market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing adoption of advanced screening platforms
-
Shift toward biologics and advanced therapeutic modalities
RESTRAINTS
Impact
Level
Level
-
High up-front investment in instruments, automation, and data infrastructure
-
Shortage of skilled personnel
OPPORTUNITIES
Impact
Level
Level
-
Growing demand for in-silico based discovery
-
Increasing need for specialized ADME/Toxicology testing
CHALLENGES
Impact
Level
Level
-
Assay reproducibility and standardization issues
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing adoption of advanced screening platforms
Pharmaceutical and biotech firms are increasingly adopting advanced screening solutions to improve early-stage discovery. High-throughput screening solutions enable higher accuracy in screening a large number of compounds in a short time. Moreover, these solutions help companies make quicker decisions, which is becoming a norm in a competitive pharmaceutical discovery and development environment.
Restraint: High up-front investment in instruments, automation, and data infrastructure
Implementing advanced screening technologies involves high initial costs. Companies must invest in specialized instruments, automation systems, and supporting software to enhance their operations. Additional spending is needed for data storage, integration, and analysis capabilities. Small business organizations and mid-sized companies face budget complexities because of these expenditures. Even if these solutions have a positive impact in the future, budgetary issues might cause lagged implementation.
Opportunity: Growing demand for in-silico based discovery
In-silico discovery is gaining wider acceptance as companies look to reduce early research costs and timelines. Digital models help screen targets and compounds before lab testing begins. This enables teams to allocate their resources to the most promising candidates. As software tools improve and integrate with lab workflows, in-silico approaches are finding a practical and significant part of drug discovery programs.
Challenge: Assay reproducibility and standardization issues
One of the most important challenges in the drug discovery technologies market is ensuring a standardized outcome from the assay across different laboratories. A small variation in protocols, materials, and handling methods can affect the results. This makes it harder to trust the data and compare results between different studies. The absence of widely accepted standards adds to the problem. Companies must invest time in validation and process alignment to improve consistency and support confident decision-making.
DRUG DISCOVERY TECHNOLOGIES MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Used its AI platforms (e.g., PandaOmics, Chemistry42) to design and generate novel drug candidates for idiopathic pulmonary fibrosis and advance them into clinical trials in significantly accelerated timelines | Reduced discovery time from years to months | Enabled rapid progression to preclinical/Phase I trials and validated AI-designed drugs in humans |
 |
Combined machine learning with automated biological experiments at scale to discover treatment candidates for genetic diseases | Increased discovery throughput | Faster identification of novel targets | Scalable platform for multiple indications |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The drug discovery technologies market ecosystem comprises manufacturers (Revvity, Danaher, Agilent, Hamilton), regulatory bodies (European Medicines Agency, US FDA, UK Government), raw material suppliers (Merck, Thorlabs, Hamamatsu), and end users (Novartis, Pfizer, MIT). Raw material suppliers provide reagents, optical components, and consumables used by manufacturers to develop screening, analytical, and automation tools. Regulatory bodies est specifications for data quality, validation, and compliance requirements. End users, such as pharmaceutical firms and research institutes, implement these solutions in order to assist in molecular target identification, screening, and early-stage drug development.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Drug Discovery Technologies Market, By Product
In 2024, reagents & consumables dominated the drug discovery technologies market. This dominance is attributed to the frequent use of reagents and consumables across screening, assay development, and validation steps, their recurring purchase cycle, and consistent demand from ongoing drug discovery and research activities.
Drug Discovery Technologies Market, By Technology
In 2024, the high-throughput screening technologies segment dominated the drug discovery technologies market, driven by the need for faster compound evaluation. They allow large-scale testing, improve productivity in early discovery, and support quicker decisions, making them essential for pharmaceutical and biotechnology research programs.
Drug Discovery Technologies Market, By Therapeutic Area
In 2024, oncology dominated the drug discovery technologies market, driven by the high disease burden and a strong focus on R&D. Continuous target discovery, large clinical pipelines, and heavy use of screening and analytical technologies sustain high demand across drug discovery programs.
REGION
Asia Pacific to be fastest-growing region in global aerospace materials market during forecast period
DRUG DISCOVERY TECHNOLOGIES MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX
In the drug discovery technologies market company evaluation matrix, Thermo Fisher Scientific Inc. (Star) has a strong presence across early drug discovery activities. The company offers a wide range of instruments, reagents, and basic software commonly used in target research to preclinical work. Its large scale, steady supply, and consistent performance make it a trusted choice for many pharmaceutical and biotechnology companies. Danaher Corporation (Emerging Leader) has been expanding its life sciences businesses and strengthening its role in laboratory research. Its focus on automation, biologics-related tools, and flexible lab systems is helping it increase adoption in drug discovery settings.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Agilent Technologies, Inc. (US)
- Illumina, Inc. (US)
- Revvity (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bruker (US)
- QIAGEN (Germany)
- Bio-Rad Laboratories, Inc. (US)
- Tecan Trading AG (Switzerland)
- Takara Bio Inc. (Japan)
- Corning Incorporated (US)
- Hamilton Company (US)
- PacBio (US)
- Oxford Nanopore Technologies plc (UK)
- Promega Corporation (US)
- Waters Corporation (US)
- Merck KGAA (Germany)
- Sartorius AG (Germany)
- BD (US)
- Eppendorf SE (Germany)
- Shimadzu Corporation (Japan)
- Aurora Biomed Inc. (Canada)
- Standard BioTools (US)
- Jeol Ltd. (Japan)
- Gilson Incorporated (US)
- BIOMÉRIEUX (France)
- Greiner AG (Austria)
- BGI Group (China)
- Porvair (UK)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 28.61 Billion |
| Market Forecast in 2030 (Value) | USD 51.51 Billion |
| Growth Rate | CAGR of 11.0% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
WHAT IS IN IT FOR YOU: DRUG DISCOVERY TECHNOLOGIES MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown |
|
Provides granular country-level insights, enabling clients to prioritize high-growth markets, and tailor portfolio strategies across instruments processing for maximum regional impact |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- October 2025 : Thermo Fisher Scientific announced a research and development (R&D) partnership with AstraZeneca BioVentureHub, focusing on chromatography, molecular genomics, and proteomics.
- May 2025 : Danaher announced a strategic partnership with AstraZeneca to develop and commercialize AI-driven diagnostic and analytical platforms. These tools aim to accelerate target identification, biomarker validation, and patient stratification, supporting more efficient drug discovery and precision therapy development.
- April 2025 : Revvity launched Signals One Unified Data Platform, an integrated software solution designed to accelerate drug discovery by unifying experimental data, enabling AI-driven analytics, and streamlining workflows across design, testing, and decision-making processes.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
42
2
EXECUTIVE SUMMARY
47
3
PREMIUM INSIGHTS
53
4
MARKET OVERVIEW
Embrace 3D models and automation to capitalize on biologics and advanced therapeutics growth.
56
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
INCREASING ADOPTION OF ADVANCED SCREENING PLATFORMS
4.2.1.2
SHIFT TOWARD BIOLOGICS AND ADVANCED THERAPEUTIC MODALITIES
4.2.1.3
TRANSITION FROM CONVENTIONAL TWO-DIMENSIONAL CULTURES TO THREE-DIMENSIONAL MODELS
4.2.1.4
TECHNOLOGICAL INNOVATIONS IN ASSAY MINIATURIZATION AND AUTOMATION
4.2.2
RESTRAINTS
4.2.2.1
HIGH UP-FRONT INVESTMENT IN INSTRUMENTS, AUTOMATION, AND DATA INFRASTRUCTURE
4.2.2.2
SHORTAGE OF SKILLED PERSONNEL
4.2.3
OPPORTUNITIES
4.2.3.1
GROWING DEMAND FOR IN-SILICO-BASED DISCOVERY
4.2.3.2
INCREASING NEED FOR SPECIALIZED ADME/TOXICOLOGY TESTING
4.2.4
CHALLENGES
4.2.4.1
ASSAY REPRODUCIBILITY AND STANDARDIZATION ISSUES
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Navigate competitive forces and pricing trends to optimize strategy in the evolving healthcare industry.
64
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
INTENSITY OF COMPETITIVE RIVALRY
5.1.2
BARGAINING POWER OF SUPPLIERS
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
THREAT OF NEW ENTRANTS
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
R&D TRENDS IN GLOBAL PHARMA INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024
5.5.2
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024
5.5.2.1
AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024
5.5.2.2
AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2024
5.5.3
AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022−2024
5.5.4
AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024
5.6
TRADE ANALYSIS
5.6.1
IMPORT SCENARIO FOR HS CODE 3822.00
5.6.2
EXPORT SCENARIO FOR HS CODE 3822.00
5.6.3
IMPORT SCENARIO FOR HS CODE 9027.00
5.6.4
EXPORT SCENARIO FOR HS CODE 9027.00
5.7
KEY CONFERENCES AND EVENTS, 2025–2026
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.10
CASE STUDY ANALYSIS
5.10.1
AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT
5.10.2
INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY
5.10.3
NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN
5.11
IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET
5.11.1
INTRODUCTION
5.11.2
KEY TARIFF RATES
5.11.3
PRICE IMPACT ANALYSIS
5.11.4
KEY IMPACT ON COUNTRIES/REGIONS
5.11.4.1
US
5.11.4.2
EUROPE
5.11.4.3
ASIA PACIFIC
5.11.5
END-USE INDUSTRY IMPACT
5.11.5.1
PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
5.11.5.2
ACADEMIC AND RESEARCH INSTITUTES
5.11.5.3
CONTRACT RESEARCH ORGANIZATIONS (CROS)
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven advancements redefine drug discovery with automation, patents, and future-ready molecular design.
89
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION
6.1.2
AUTOMATED LIQUID HANDLING
6.2
ADJACENT TECHNOLOGIES
6.2.1
AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS
6.2.2
DISCOVERY INFORMATICS & LAB DIGITALIZATION
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.4
PATENT ANALYSIS
6.4.1
METHODOLOGY
6.4.2
NUMBER OF PATENTS FILED
6.4.3
LIST OF KEY PATENTS
6.5
FUTURE APPLICATIONS
6.6
IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
Navigate global sustainability regulations and certifications to enhance compliance and market positioning.
98
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.1.2.1
NORTH AMERICA
7.1.2.1.1
US
7.1.2.1.2
CANADA
7.1.2.2
EUROPE
7.1.2.2.1
UK
7.1.2.3
ASIA PACIFIC
7.1.2.3.1
CHINA
7.1.2.3.2
JAPAN
7.1.2.3.3
INDIA
7.1.2.3.4
SOUTH KOREA
7.1.2.3.5
AUSTRALIA
7.1.2.3.6
REST OF ASIA PACIFIC
7.2
SUSTAINABILITY INITIATIVES
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOUR
Uncover critical buyer influences and unmet needs shaping industry purchasing decisions.
107
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
KEY BUYING CRITERIA, BY END USER
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
111
9.1
INTRODUCTION
9.2
REAGENTS & CONSUMABLES
9.2.1
INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH
9.3
INSTRUMENTS
9.3.1
HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET
9.4
BIOINFORMATICS TOOLS & SOFTWARE
9.4.1
AI-RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET
10
DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 85 Data Tables
123
10.1
INTRODUCTION
10.2
HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES
10.2.1
AUTOMATED LIQUID HANDLING
10.2.1.1
INCREASING FOCUS ON PRECISION, INTEGRATION, AND PRODUCTIVITY TO DRIVE MARKET
10.2.2
MICROPLATE-BASED HTS
10.2.2.1
RISING INVESTMENTS IN PHARMACEUTICAL AND BIOTECHNOLOGY R&D TO FUEL MARKET
10.2.3
LAB-ON-A CHIP
10.2.3.1
INCREASING DEMAND FOR MORE PREDICTIVE PRECLINICAL MODELS TO BOOST MARKET
10.2.4
LABEL-FREE TECHNOLOGY
10.2.4.1
REAL-TIME, LABEL-FREE INTERACTION TO ACCELERATE SEGMENT GROWTH
10.3
NEXT-GENERATION SEQUENCING
10.3.1
EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET
10.4
POLYMERASE CHAIN REACTION
10.4.1
ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET
10.5
IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES
10.5.1
COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET
10.6
X-RAY CRYSTALLOGRAPHY
10.6.1
ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET
10.7
CHROMATOGRAPHY
10.7.1
REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH
10.8
MASS SPECTROMETRY
10.8.1
INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET
10.9
OTHER TECHNOLOGIES
11
DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 36 Data Tables
167
11.1
INTRODUCTION
11.2
TARGET IDENTIFICATION
11.2.1
INCREASING CLINICAL DATA VOLUME TO BOOST MARKET
11.3
TARGET VALIDATION
11.3.1
INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH
11.4
HIT-TO-LEAD IDENTIFICATION
11.4.1
GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET
11.5
LEAD OPTIMIZATION
11.5.1
INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET
11.6
CANDIDATE VALIDATION
11.6.1
INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH
12
DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 50 Data Tables
186
12.1
INTRODUCTION
12.2
ONCOLOGY
12.2.1
SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH
12.3
INFECTIOUS DISEASES
12.3.1
RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET
12.4
CARDIOVASCULAR DISEASES
12.4.1
INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET
12.5
NEUROLOGICAL DISEASES
12.5.1
INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET
12.6
ENDOCRINE & METABOLIC DISORDERS
12.6.1
RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET
12.7
AUTOIMMUNE DISORDERS
12.7.1
WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET
12.8
OTHER THERAPEUTIC AREAS
13
DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
212
13.1
INTRODUCTION
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1
TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRBUTE TO GROWTH
13.3
ACADEMIC & RESEARCH INSTITUTES
13.3.1
RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC–INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH
13.4
CONTRACT RESEARCH ORGANIZATIONS (CROS)
13.4.1
INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH
14
DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 175 Data Tables.
224
14.1
INTRODUCTION
14.2
NORTH AMERICA
14.2.1
US
14.2.1.1
EXPANDING NETWORK OF CROSS-BORDER PARTNERSHIPS AND INVESTMENTS TO EXPEDITE GROWTH
14.2.2
CANADA
14.2.2.1
INCREASING ADOPTION OF AI AND OPEN-SCIENCE MODELS TO ACCELERATE GROWTH
14.3
EUROPE
14.3.1
GERMANY
14.3.1.1
STRONG NETWORK OF PUBLICLY FUNDED RESEARCH INSTITUTES, CONTRACT RESEARCH ORGANIZATIONS, AND PHARMACEUTICAL DEVELOPERS TO BOOST MARKET
14.3.2
UK
14.3.2.1
INCREASING FOCUS ON NEXT-GENERATION COMPUTATIONAL PLATFORMS TO PROMOTE GROWTH
14.3.3
FRANCE
14.3.3.1
ROBUST INNOVATION ECOSYSTEM AND AI-ENABLED RESEARCH TO PROPEL MARKET
14.3.4
ITALY
14.3.4.1
RISING RESEARCH FUNDING TO CONTRIBUTE TO GROWTH
14.3.5
SPAIN
14.3.5.1
WELL-ESTABLISHED NETWORK OF RESEARCH CENTERS AND UNIVERSITIES TO BOOST MARKET
14.3.6
REST OF EUROPE
14.4
ASIA PACIFIC
14.4.1
CHINA
14.4.1.1
GLOBAL PARTNERSHIPS TO PROPEL MARKET
14.4.2
JAPAN
14.4.2.1
RISING INTEGRATION OF AI AND INTERNATIONAL PARTNERSHIPS TO FAVOR GROWTH
14.4.3
INDIA
14.4.3.1
DOMESTIC INFRASTRUCTURE ENHANCEMENTS AND GOVERNMENT INITIATIVES TO SUPPORT GROWTH
14.4.4
AUSTRALIA
14.4.4.1
RISING ADOPTION OF ARTIFICIAL INTELLIGENCE AND ADVANCED COMPUTATIONAL TOOLS TO FOSTER GROWTH
14.4.5
SOUTH KOREA
14.4.5.1
FAVORABLE PUBLIC POLICIES TO SUPPORT GROWTH
14.4.6
REST OF ASIA PACIFIC
14.5
LATIN AMERICA
14.5.1
BRAZIL
14.5.1.1
PUBLIC-PRIVATE COLLABORATIONS TO BOLSTER GROWTH
14.5.2
MEXICO
14.5.2.1
RISING DEMAND FOR AI-POWERED RESEARCH TO SUPPORT GROWTH
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST
14.6.1
GCC COUNTRIES
14.6.1.1
SAUDI ARABIA
14.6.1.1.1
INCREASING FOCUS ON REGULATORY REFORM, RESEARCH FUNDING, AND INTERNATIONAL PARTNERSHIPS TO BOOST MARKET
14.6.1.2
UAE
14.6.1.2.1
STRONG GOVERNMENT VISION AND CROSS-SECTOR PARTNERSHIPS TO AID GROWTH
14.6.1.3
REST OF GCC COUNTRIES
14.6.2
REST OF MIDDLE EAST
14.7
AFRICA
14.7.1
STRATEGIC PARTNERSHIPS AND CAPACITY-BUILDING INITIATIVES TO PROPEL MARKET
15
COMPETITIVE LANDSCAPE
Uncover market leaders' strategies and competitive positioning through detailed revenue and share analysis.
327
15.1
OVERVIEW
15.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
15.3
REVENUE ANALYSIS
15.4
MARKET SHARE ANALYSIS
15.5
BRAND/PRODUCT COMPARISON
15.5.1
THERMO FISHER SCIENTIFIC INC.
15.5.2
MERCK KGAA
15.5.3
AGILENT TECHNOLOGIES, INC.
15.5.4
REVVITY
15.5.5
ILLUMINA, INC.
15.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
15.6.1
STARS
15.6.2
EMERGING LEADERS
15.6.3
PERVASIVE PLAYERS
15.6.4
PARTICIPANTS
15.6.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.6.5.1
COMPANY FOOTPRINT
15.6.5.2
REGION FOOTPRINT
15.6.5.3
PRODUCT FOOTPRINT
15.6.5.4
TECHNOLOGY FOOTPRINT
15.6.5.5
PROCESS FOOTPRINT
15.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
15.7.1
PROGRESSIVE COMPANIES
15.7.2
RESPONSIVE COMPANIES
15.7.3
DYNAMIC COMPANIES
15.7.4
STARTING BLOCKS
15.7.5
COMPETITIVE BENCHMARKING
15.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.8
COMPANY VALUATION AND FINANCIAL METRICS
15.9
COMPETITIVE SCENARIO
15.9.1
PRODUCT LAUNCHES
15.9.2
DEALS
15.9.3
EXPANSIONS
15.9.4
OTHER DEVELOPMENTS
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
349
16.1
KEY PLAYERS
16.1.1
THERMO FISHER SCIENTIFIC INC.
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.3.1
PRODUCT LAUNCHES
16.1.1.3.2
DEALS
16.1.1.3.3
EXPANSIONS
16.1.1.4
MNM VIEW
16.1.1.4.1
KEY STRENGTHS/RIGHT TO WIN
16.1.1.4.2
STRATEGIC CHOICES
16.1.1.4.3
WEAKNESSES/COMPETITIVE THREATS
16.1.2
MERCK KGAA
16.1.3
AGILENT TECHNOLOGIES, INC.
16.1.4
REVVITY
16.1.5
ILLUMINA, INC.
16.1.6
DANAHER CORPORATION
16.1.7
F. HOFFMANN-LA ROCHE LTD
16.1.8
BRUKER
16.1.9
QIAGEN
16.1.10
BIO-RAD LABORATORIES, INC.
16.1.11
TECAN TRADING AG
16.1.12
TAKARA BIO INC.
16.1.13
CORNING INCORPORATED
16.1.14
HAMILTON COMPANY
16.1.15
PACBIO
16.1.16
OXFORD NANOPORE TECHNOLOGIES PLC
16.1.17
PROMEGA CORPORATION
16.1.18
WATERS CORPORATION
16.1.19
SARTORIUS AG
16.1.20
BD
16.1.21
EPPENDORF SE
16.1.22
SHIMADZU CORPORATION
16.1.23
AURORA BIOMED INC.
16.1.24
STANDARD BIOTOOLS
16.1.25
JEOL LTD.
16.1.26
GILSON INCORPORATED
16.1.27
BIOMÉRIEUX
16.1.28
GREINER AG
16.1.29
BGI GROUP
16.1.30
PORVAIR
16.2
OTHER PLAYERS
16.2.1
POLARIS GENOMICS
16.2.2
BICO
16.2.3
CREATIVE BIOARRAY
16.2.4
SPHERE BIO
16.2.5
GENSCRIPT
16.2.6
SCHRÖDINGER, INC.
16.2.7
LECO CORPORATION
16.2.8
TRANSGEN BIOTECH CO., LTD
16.2.9
BMG LABTECH
16.2.10
NANOTEMPER TECHNOLOGIES
16.2.11
MGI TECH CO., LTD.
16.2.12
ARACELI BIOSCIENCES
16.2.13
ANALYTIK JENA GMBH+CO. KG
16.2.14
BIOSOLVEIT GMBH
16.2.15
EVOSEP
17
RESEARCH METHODOLOGY
467
17.1
RESEARCH DATA
17.1.1
SECONDARY DATA
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2
PRIMARY DATA
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY PRIMARY PARTICIPANTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.2
TOP-DOWN APPROACH
17.2.3
BASE NUMBER CALCULATION
17.3
GROWTH FORECAST MODEL
17.4
DATA TRIANGULATION
17.5
FACTOR ANALYSIS
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
18
APPENDIX
481
18.1
DISCUSSION GUIDE
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.4
RELATED REPORTS
18.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
DRUG DISCOVERY TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
DRUG DISCOVERY TECHNOLOGIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3
DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES
TABLE 4
DRUG DISCOVERY TECHNOLOGIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 5
AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYERS, 2024
TABLE 6
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION)
TABLE 7
AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022−2024
TABLE 8
AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION)
TABLE 9
AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2022–2024 (USD MILLION)
TABLE 10
IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 11
EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 12
IMPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 13
EXPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020–2024 (USD THOUSAND)
TABLE 14
DRUG DISCOVERY TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 15
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 16
KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO DRUG DISCOVERY TECHNOLOGIES
TABLE 17
CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 18
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
TABLE 19
LIST OF KEY PATENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2025
TABLE 20
CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET
TABLE 21
CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET
TABLE 22
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
DRUG DISCOVERY TECHNOLOGIES MARKET: VENDOR CERTIFICATIONS
TABLE 27
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 28
KEY BUYING CRITERIA, BY END USER
TABLE 29
DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 30
DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 31
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)
TABLE 36
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 38
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 43
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 52
DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 53
DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 54
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 59
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION)
TABLE 61
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION)
TABLE 66
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 67
DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 68
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE- BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 73
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023–2030 (USD MILLION)
TABLE 75
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023–2030 (USD MILLION)
TABLE 80
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 87
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 94
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 103
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION)
TABLE 109
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION)
TABLE 114
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115
DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)
TABLE 116
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)
TABLE 121
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)
TABLE 123
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)
TABLE 128
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 130
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 132
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 135
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 137
DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 138
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 143
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 145
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 150
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 152
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 157
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 159
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 164
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 166
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 171
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172
DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 173
DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 174
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 177
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 179
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180
DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 181
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 186
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187
DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 188
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 193
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194
DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 195
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 199
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 200
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 201
DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 202
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 204
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 207
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208
DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 209
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 210
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 213
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 214
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 215
DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 216
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 217
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 218
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 220
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 221
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222
DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 223
DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 224
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 225
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 227
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 229
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230
DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 231
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 234
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 236
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 237
DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION)
TABLE 238
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 239
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 240
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 241
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 242
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION)
TABLE 243
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 244
DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 245
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 246
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 247
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 248
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 249
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 250
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 251
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 252
US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 253
US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 254
US: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 255
US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 256
US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 257
US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 258
CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 259
CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 260
CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 261
CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 262
CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 263
CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 264
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 265
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 266
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 267
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 268
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 269
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 270
EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 271
GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 272
GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 273
GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 274
GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 275
GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 276
GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 277
UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 278
UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 279
UK: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280
UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 281
UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 282
UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 283
FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 284
FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 285
FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 286
FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 287
FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 288
FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 289
ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 290
ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 291
ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 292
ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 293
ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 294
ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 295
SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 296
SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 297
SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 298
SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 299
SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 300
SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 301
REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 302
REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 303
REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 304
REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 305
REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 306
REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 307
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 308
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 309
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 310
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 311
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 312
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 313
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 314
CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 315
CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 316
CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 317
CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 318
CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 319
CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 320
JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 321
JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 322
JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 323
JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 324
JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 325
JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 326
INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 327
INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 328
INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329
INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 330
INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 331
INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 332
AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 333
AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 334
AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 335
AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 336
AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 337
AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 338
SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 339
SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 340
SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 341
SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 342
SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 343
SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 344
REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 345
REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 346
REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 347
REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 348
REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 349
REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 350
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 351
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 352
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 353
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 354
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 355
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 356
LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 357
BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 358
BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 359
BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 360
BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 361
BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 362
BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 363
MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 364
MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 365
MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 366
MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 367
MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 368
MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 369
REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 370
REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 371
REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 372
REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 373
REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 374
REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 375
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 376
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 377
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 378
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 379
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 380
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 381
MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 382
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 383
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 384
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 385
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 386
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 387
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 388
GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 389
SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 390
SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 391
SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 392
SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 393
SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 394
SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 395
UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 396
UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 397
UAE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 398
UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 399
UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 400
UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 401
REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 402
REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 403
REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 404
REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 405
REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 406
REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 407
REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 408
REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 409
REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 410
REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 411
REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 412
REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 413
AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 414
AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 415
AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 416
AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)
TABLE 417
AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 418
AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 419
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2022–NOVEMBER 2025
TABLE 420
DRUG DISCOVERY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
TABLE 421
DRUG DISCOVERY TECHNOLOGIES MARKET: REGION FOOTPRINT
TABLE 422
DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
TABLE 423
DRUG DISCOVERY TECHNOLOGIES MARKET: TECHNOLOGY FOOTPRINT
TABLE 424
DRUG DISCOVERY TECHNOLOGIES MARKET: PROCESS FOOTPRINT
TABLE 425
DRUG DISCOVERY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 426
DRUG DISCOVERY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 427
DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 428
DRUG DISCOVERY TECHNOLOGIES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 429
DRUG DISCOVERY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 430
DRUG DISCOVERY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025
TABLE 431
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 432
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 433
THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 434
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 435
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 436
MERCK KGAA: COMPANY OVERVIEW
TABLE 437
MERCK KGAA: PRODUCTS OFFERED
TABLE 438
MERCK KGAA: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 439
MERCK KGAA: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 440
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 441
AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 442
AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 443
AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 444
REVVITY: COMPANY OVERVIEW
TABLE 445
REVVITY: PRODUCTS OFFERED
TABLE 446
REVVITY: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 447
REVVITY: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 448
REVVITY: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 449
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 450
ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 451
ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 452
ILLUMINA, INC.: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 453
ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 454
ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025
TABLE 455
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 456
DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 457
DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 458
DANAHER CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 459
DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 460
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 461
F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 462
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 463
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 464
F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025
TABLE 465
BRUKER: COMPANY OVERVIEW
TABLE 466
BRUKER: PRODUCTS OFFERED
TABLE 467
BRUKER: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 468
BRUKER: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 469
BRUKER: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 470
QIAGEN: COMPANY OVERVIEW
TABLE 471
QIAGEN: PRODUCTS OFFERED
TABLE 472
QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 473
QIAGEN: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 474
QIAGEN: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 475
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 476
BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 477
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 478
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 479
TECAN TRADING AG: COMPANY OVERVIEW
TABLE 480
TECAN TRADING AG: PRODUCTS OFFERED
TABLE 481
TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 482
TAKARA BIO INC.: PRODUCTS OFFERED
TABLE 483
TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 484
CORNING INCORPORATED: COMPANY OVERVIEW
TABLE 485
CORNING INCORPORATED: PRODUCTS OFFERED
TABLE 486
HAMILTON COMPANY: COMPANY OVERVIEW
TABLE 487
HAMILTON COMPANY: PRODUCTS OFFERED
TABLE 488
HAMILTON COMPANY: PRODUCT LAUNCHES
TABLE 489
HAMILTON COMPANY: DEALS
TABLE 490
PACBIO: COMPANY OVERVIEW
TABLE 491
PACBIO: PRODUCTS OFFERED
TABLE 492
PACBIO: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 493
PACBIO: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
TABLE 494
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 495
OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS OFFERED
TABLE 496
OXFORD NANOPORE TECHNOLOGIES PLC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 497
OXFORD NANOPORE TECHNOLOGIES PLC.: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 498
PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 499
PROMEGA CORPORATION: PRODUCTS OFFERED
TABLE 500
WATERS CORPORATION: COMPANY OVERVIEW
TABLE 501
WATERS CORPORATION: PRODUCTS OFFERED
TABLE 502
WATERS CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 503
WATERS CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 504
SARTORIUS AG: COMPANY OVERVIEW
TABLE 505
SARTORIUS AG: PRODUCTS OFFERED
TABLE 506
SARTORIUS AG: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 507
BD: COMPANY OVERVIEW
TABLE 508
BD: PRODUCTS OFFERED
TABLE 509
BD: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025
TABLE 510
BD: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 511
EPPENDORF SE: COMPANY OVERVIEW
TABLE 512
EPPENDORF SE: PRODUCTS OFFERED
TABLE 513
EPPENDORF SE: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 514
SHIMADZU CORPORATION: COMPANY OVERVIEW
TABLE 515
SHIMADZU CORPORATION: PRODUCTS OFFERED
TABLE 516
AURORA BIOMED INC.: COMPANY OVERVIEW
TABLE 517
AURORA BIOMED INC.: PRODUCTS OFFERED
TABLE 518
STANDARD BIOTOOLS: COMPANY OVERVIEW
TABLE 519
STANDARD BIOTOOLS: PRODUCTS OFFERED
TABLE 520
JEOL LTD.: COMPANY OVERVIEW
TABLE 521
JEOL LTD.: PRODUCTS OFFERED
TABLE 522
GILSON INCORPORATED: COMPANY OVERVIEW
TABLE 523
GILSON INCORPORATED: PRODUCTS OFFERED
TABLE 524
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 525
BIOMÉRIEUX: PRODUCTS OFFERED
TABLE 526
GREINER AG: COMPANY OVERVIEW
TABLE 527
GREINER AG: PRODUCTS OFFERED
TABLE 528
BGI GROUP: COMPANY OVERVIEW
TABLE 529
BGI GROUP: PRODUCTS OFFERED
TABLE 530
PORVAIR: COMPANY OVERVIEW
TABLE 531
PORVAIR: PRODUCTS OFFERED
TABLE 532
POLARIS GENOMICS: COMPANY OVERVIEW
TABLE 533
BICO: COMPANY OVERVIEW
TABLE 534
CREATIVE BIOARRAY: COMPANY OVERVIEW
TABLE 535
SPHERE BIO: COMPANY OVERVIEW
TABLE 536
GENSCRIPT: COMPANY OVERVIEW
TABLE 537
SCHRÖDINGER, INC.: COMPANY OVERVIEW
TABLE 538
LECO CORPORATION: COMPANY OVERVIEW
TABLE 539
TRANSGEN BIOTECH CO., LTD: COMPANY OVERVIEW
TABLE 540
BMG LABTECH: COMPANY OVERVIEW
TABLE 541
NANOTEMPER TECHNOLOGIES: COMPANY OVERVIEW
TABLE 542
MGI TECH CO., LTD.: COMPANY OVERVIEW
TABLE 543
ARACELI BIOSCIENCES: COMPANY OVERVIEW
TABLE 544
ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
TABLE 545
BIOSOLVEIT GMBH: COMPANY OVERVIEW
TABLE 546
EVOSEP: COMPANY OVERVIEW
TABLE 547
IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
TABLE 548
RISK ASSESSMENT
LIST OF FIGURES
FIGURE 1
DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION AND REGIONS CONSIDERED
FIGURE 2
DRUG DISCOVERY TECHNOLOGIES MARKET: YEARS CONSIDERED
FIGURE 3
MARKET SCENARIO
FIGURE 4
GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2030
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2022–2025
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF DRUG DISCOVERY TECHNOLOGIES MARKET
FIGURE 7
HIGH-GROWTH SEGMENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2025–2030
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG DISCOVERY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9
REAGENTS & CONSUMABLES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024
FIGURE 10
ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN DRUG DISCOVERY TECHNOLOGIES MARKET DURING FORECAST PERIOD
FIGURE 11
REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12
DRUG DISCOVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13
DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 14
GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECASTS UNTIL 2030
FIGURE 15
DRUG DISCOVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
FIGURE 16
DRUG DISCOVERY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
FIGURE 17
AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)
FIGURE 18
AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2024 (USD)
FIGURE 19
AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)
FIGURE 20
AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2024 (USD MILLION)
FIGURE 21
DRUG DISCOVERY TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 22
DRUG DISCOVERY TECHNOLOGIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025 (USD MILLION)
FIGURE 23
PATENT APPLICATIONS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2014–DECEMBER 2024
FIGURE 24
IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET
FIGURE 25
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 26
KEY BUYING CRITERIA, BY END USER
FIGURE 27
NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT
FIGURE 28
ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT
FIGURE 29
REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024
FIGURE 30
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 31
DRUG DISCOVERY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARISON
FIGURE 32
DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 33
DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT
FIGURE 34
DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 35
EV/EBITDA OF KEY VENDORS
FIGURE 36
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 37
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 38
MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 39
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 40
REVVITY: COMPANY SNAPSHOT (2024)
FIGURE 41
ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
FIGURE 42
DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 43
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
FIGURE 44
BRUKER: COMPANY SNAPSHOT (2024)
FIGURE 45
QIAGEN: COMPANY SNAPSHOT (2024)
FIGURE 46
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 47
TECAN TRADING AG: COMPANY SNAPSHOT (2024)
FIGURE 48
TAKARA BIO INC.: COMPANY SNAPSHOT (2024)
FIGURE 49
CORNING INCORPORATED: COMPANY SNAPSHOT (2024)
FIGURE 50
PACBIO: COMPANY SNAPSHOT (2024)
FIGURE 51
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
FIGURE 52
WATERS CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 53
SARTORIUS AG: COMPANY SNAPSHOT (2024)
FIGURE 54
BD: COMPANY SNAPSHOT (2024)
FIGURE 55
EPPENDORF SE: COMPANY SNAPSHOT (2024)
FIGURE 56
SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 57
STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024)
FIGURE 58
JEOL LTD.: COMPANY SNAPSHOT
FIGURE 59
BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
FIGURE 60
GREINER AG: COMPANY SNAPSHOT (2024)
FIGURE 61
PORVAIR: COMPANY SNAPSHOT (2024)
FIGURE 62
DRUG DISCOVERY TECHNOLOGIES MARKET: RESEARCH DESIGN
FIGURE 63
DRUG DISCOVERY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 64
DRUG DISCOVERY TECHNOLOGIES MARKET: INSIGHTS FROM PRIMARIES
FIGURE 65
DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024)
FIGURE 66
ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2024)
FIGURE 67
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 68
DRUG DISCOVERY TECHNOLOGIES BASE NUMBER CALCULATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 69
DRUG DISCOVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS
FIGURE 70
DRUG DISCOVERY TECHNOLOGIES MARKET: DATA TRIANGULATION
Methodology
The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery technologies market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery technologies market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery technologies market, which was further validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery technologies market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery technologies are provided by contract research organizations (CROs) to pharmaceutical companies.
Stakeholders
- Drug discovery service providers
- Pharmaceutical and biotechnology companies
- Academic & Research Institutes
- Contract Research Organization
- Market Research and Consulting Firms
- R&D Centers
- Researchers and Scientists
- Regulatory Agencies
- Venture Capitalists
- Government Organizations
- Industry Associations and Professional Societies
Report Objectives
- To define, describe, and forecast the drug discovery technologies market by value by process, type, drug type, therapeutic area, end user and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery technologies market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Drug Discovery Technologies Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Drug Discovery Technologies Market